BioSpace News Archive

Epigenomics AG announced the financial results for the first quarter of the FY 2019.

Monocl has been appointed to the Veeva Technology Partner Program, bringing the industry-leading stakeholder insights from Monocl seamlessly into Veeva CRM.

Eisai Co., Ltd. announced that the company has commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with those businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform.

MyoKardia, Inc. announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15th, 2019, at 8:40 a.m. PT (11:40 a.m. ET) in Las Vegas, NV.

Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care.

The company announced today that the drug failed to meet its primary endpoint in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM), a type of brain cancer.

John Orloff and Brian Goff spoke with BioSpace about Alexion and new trends and developments the company is reporting.

BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease.

New funding will enable pharmaceutical group to accelerate program of international growth through acquisitions

Corporate LiveWire acknowledges the importance of a patient-accepted CRC detection method to effectively diagnose colorectal cancer.